Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1425634
This article is part of the Research Topic Advances in precision medicine in the management of thyroid nodules and thyroid cancer View all 32 articles

Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Differentiated Thyroid Cancer in the US

Provisionally accepted
Yang Shi Yang Shi Lv Chengzhou Lv Chengzhou Pai Liu Pai Liu Yuenan Zheng Yuenan Zheng Hao Zhang Hao Zhang Wenwu Dong Wenwu Dong *Ping Zhang Ping Zhang *
  • Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China

The final, formatted version of the article will be published soon.

    Background: Limited information is available regarding the relative risks of cancer-specific mortality and noncancer-specific mortality among long-term survivors with differentiated thyroid cancer (DTC).In this retrospective study, nationwide data from the Surveillance, Epidemiology, and End Results database (1992-2020) were utilized. The Accelerated Failure Time Model was applied to calculate Survival Time Ratios (TR), with the primary focus on mortality resulting from DTC. The competing risks model was employed to investigate the relative risks of various outcomes in DTC patients with a survival duration of 5 years or more.Results: In our cohort, 279 patients succumbed to DTC, while 748 died from other diseases. Notably, in DTC cohorts, noncancer-specific mortality rates were consistently higher than DTC-specific mortality rates across different age groups and genders. The risk of DTC and noncancer-specific mortality varied based on the TNM stage. With more advanced disease stages, the risk of DTC and other cancer-specific mortality gradually increased. The cumulative mortality from other cancer-specific causes was consistently the lowest.In long-term surviving DTC patients, noncancer-specific mortality outweighed DTC-specific mortality irrespective of age and gender. For stage I and II patients, increased attention should be directed toward noncancer-specific mortality in postoperative follow-ups. Conversely, for stage III and IV patients, greater consideration should be given to DTC-related causes of death. In addition, for stage III and IV DTC patients, the risk of death from other cancers was significantly higher than for stages I and II.

    Keywords: Differentiated thyroid cancer, prognosis, competing risks model, DTC, SEER

    Received: 30 Apr 2024; Accepted: 10 Oct 2024.

    Copyright: © 2024 Shi, Chengzhou, Liu, Zheng, Zhang, Dong and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Wenwu Dong, Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China
    Ping Zhang, Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.